The new findings promise to boost the effectiveness of cancer immunotherapy

Researchers have found that a specific molecule can help strengthen the function of degeneration cells, which could be used to improve treatment in the future, given their important role in cancer immunotherapy, the University of Edinburgh said in a statement.
in the event of an infection, the body produces a molecule called LL-37, which helps kill harmful bacteria and viruses. An international team led by researchers at the University of Edinburgh found that the molecules can also affect immune cells and enhance their function, especially in the form of tyroblades.
tyroblast cells have been used in cancer treatment. It is the control of the body's immune system, which activates other immune cells and prompts them to attack tumors. In cancer treatment, researchers need to take cell samples from cancer patients, grow them in the lab, and re-inject them into them, but this is expensive and inefficient.
study, published recently in the British journal Oncology Immunology, showed that researchers were able to produce more cells suitable for clinical use by adding LL-37 to the lab's process of growing dedes. They then used the protrusive cells grown in this way to treat tumors in mice, successfully shrinking or even disappearing altogether.
early tests have shown that LL-37 has a similar effect on human cells, so this method is expected to be used in human cancer treatment.
, ph.D., of the Centre for Inflammation Research at the University of Edinburgh and one of the report's authors, said there are currently some obstacles to dendritic cell-based cancer therapy and hopes the new findings will help overcome these challenges.
relevant paper information: